In addition to EGFR, upregulation of the programmed cell death ligand 1 (PD-L1) in 46–100% of HNSCC solid tumors initiated investigation of the immune checkpoint protein as another viable therapeutic target in HNSCC [16]. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.